News Release



FOR IMMEDIATE RELEASE

Investors Contact:

Robert G. Burrows Vice President, Investor Relations **301-795-1877**

BurrowsR@ebsi.com

Media Contact:

Tracey Schmitt Vice President, Corporate Communications **301-795-1800**

SchmittT@ebsi.com

EMERGENT BIOSOLUTIONS TO RELEASE FOURTH QUARTER AND FULL YEAR 2011 FINANCIAL RESULTS AND CONDUCT A CONFERENCE CALL ON MARCH 8, 2012

ROCKVILLE, MD, January 30, 2012—Emergent BioSolutions Inc. (NYSE: EBS) announced today that it will report financial results for the fourth quarter and full year 2011 on Thursday, March 8, 2012, after market close.

Company management will host a conference call at 5:00 pm Eastern on March 8, 2012 to discuss the financial results for the fourth quarter and full twelve months of 2011, recent business developments, revenue guidance for the first quarter of 2012 and revenue and net income guidance for full year 2012. The conference call will be accessible by dialing 888/680-0878 or 617/213-4855 (international) and providing passcode 35663572. A webcast of the conference call will be accessible from the company's website at www.emergentbiosolutions.com, under "Investors".

Emergent BioSolutions is offering call participants a pre-registration option that expedites access to the call and minimizes hold times. Pre-registrants will be issued a pin number to be used when dialing into the live call which will provide quick access to the conference call by bypassing the operator upon connection. Pre-registration, while not mandatory, can be accessed using the following website: https://www.theconferencingservice.com/prereg/key.process?key=PFU8DEVX6.

A replay of the conference call will be accessible, approximately two hours following the conclusion of the call, by dialing 888/286-8010 or 617/801-6888 and using the passcode 57332722. The replay will be available through March 22, 2012. The webcast will be archived on the company's website, www.emergentbiosolutions.com, under "Investors".

About Emergent BioSolutions Inc.

Emergent BioSolutions protects and enhances life by developing and manufacturing vaccines and therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. Emergent's marketed and investigational products target infectious diseases, oncology and autoimmune disorders. Additional information about the company may be found at www.emergentbiosolutions.com.

###